Overview

Continuing Sodium Zirconium Cyclosilicate (SZC) After Discharge Study

Status:
Recruiting
Trial end date:
2023-12-22
Target enrollment:
Participant gender:
Summary
This is an open-label, randomised study in participants with chronic kidney disease (CKD) treated for hyperkalaemia (HK) whilst in hospital. The study will compare SZC to standard of care (SoC) with the goal of determining: - If continued use of SZC maintains normokalaemia (NK) better than SoC after participant discharge from the hospital. - If continued use of SZC after discharge will reduce HK related healthcare resource utilisation compared to SoC.
Phase:
Phase 4
Details
Lead Sponsor:
AstraZeneca